use of clomid in control of DMPA bleeding
Not Applicable
- Conditions
- Fertility-femalecontraceptive bleeding
- Registration Number
- PACTR201801002953256
- Lead Sponsor
- department of obstetric and gynecology, maternity hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Female
- Target Recruitment
- 250
Inclusion Criteria
any woman
at any age,
any weight,
any parity
who are DMPA user for any period who complaining of irregular uterine bleeding.
Exclusion Criteria
any general causes of vaginal bleeding as known bleeding tendency
abnormal coagulation profile
anticoagulant drugs users
or hepatic patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain Clomiphene citrate's effect on DMPA-induced bleeding?
How does Clomiphene citrate compare to other contraceptive bleeding management therapies in clinical trials?
Are there specific biomarkers that predict response to Clomiphene citrate in DMPA users?
What are the potential adverse events associated with Clomiphene citrate for DMPA bleeding control?
What combination therapies or alternative drugs are being explored for managing DMPA-related contraceptive bleeding?